Valneva SE (VALN)
USD 6.57
(2.98%)
USD 6.57
(2.98%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 134.92 Million EUR | 1.54% |
| 2022 | 150.3 Million EUR | -32.16% |
| 2021 | 221.55 Million EUR | 99.37% |
| 2020 | 111.12 Million EUR | 44.42% |
| 2019 | 76.94 Million EUR | 21.49% |
| 2018 | 63.33 Million EUR | 0.11% |
| 2017 | 63.26 Million EUR | -32.29% |
| 2016 | 93.43 Million EUR | 81.9% |
| 2015 | 51.36 Million EUR | 17.98% |
| 2014 | 43.53 Million EUR | 20.75% |
| 2013 | 36.05 Million EUR | 121.67% |
| 2012 | 16.26 Million EUR | 88.09% |
| 2011 | 8.64 Million EUR | -48.57% |
| 2010 | 16.81 Million EUR | 397.1% |
| 2009 | 3.38 Million EUR | -11.63% |
| 2008 | 3.82 Million EUR | -3.55% |
| 2007 | 3.96 Million EUR | 117.54% |
| 2006 | 1.82 Million EUR | -54.01% |
| 2005 | 3.96 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 36.13 Million EUR | -20.13% |
| 2024 Q2 | 39.57 Million EUR | 0.01% |
| 2023 Q2 | 25.19 Million EUR | -14.87% |
| 2023 Q3 | 39.38 Million EUR | 56.31% |
| 2023 Q4 | 45.24 Million EUR | 14.86% |
| 2023 FY | 152.62 Million EUR | 1.54% |
| 2023 Q1 | 29.6 Million EUR | -35.7% |
| 2022 Q3 | 32.16 Million EUR | -29.62% |
| 2022 Q2 | 45.69 Million EUR | 73.04% |
| 2022 Q1 | 26.4 Million EUR | -64.16% |
| 2022 FY | 150.3 Million EUR | -32.16% |
| 2022 Q4 | 46.03 Million EUR | 43.14% |
| 2021 FY | 221.55 Million EUR | 99.37% |
| 2021 Q1 | 39.7 Million EUR | 13.67% |
| 2021 Q2 | 59.17 Million EUR | 49.03% |
| 2021 Q3 | 48.99 Million EUR | -17.2% |
| 2021 Q4 | 73.69 Million EUR | 50.42% |
| 2020 Q3 | 27.51 Million EUR | 7.29% |
| 2020 FY | 111.12 Million EUR | 44.42% |
| 2020 Q2 | 25.64 Million EUR | 11.26% |
| 2020 Q1 | 23.04 Million EUR | -10.37% |
| 2020 Q4 | 34.93 Million EUR | 26.97% |
| 2019 FY | 76.94 Million EUR | 21.49% |
| 2019 Q2 | 16.74 Million EUR | 1.95% |
| 2019 Q1 | 16.42 Million EUR | -9.68% |
| 2019 Q3 | 18.07 Million EUR | 7.93% |
| 2019 Q4 | 25.71 Million EUR | 42.3% |
| 2018 Q4 | 18.18 Million EUR | 45.65% |
| 2018 FY | 63.33 Million EUR | 0.11% |
| 2018 Q1 | 15.84 Million EUR | -16.14% |
| 2018 Q3 | 12.48 Million EUR | -25.83% |
| 2018 Q2 | 16.83 Million EUR | 6.26% |
| 2017 Q2 | 12.95 Million EUR | -11.54% |
| 2017 FY | 63.26 Million EUR | -32.29% |
| 2017 Q4 | 18.88 Million EUR | 12.6% |
| 2017 Q3 | 16.77 Million EUR | 29.48% |
| 2017 Q1 | 14.64 Million EUR | -10.16% |
| 2016 Q1 | 13.54 Million EUR | -5.63% |
| 2016 Q2 | 49.45 Million EUR | 265.05% |
| 2016 Q3 | 14.12 Million EUR | -71.43% |
| 2016 Q4 | 16.3 Million EUR | 15.4% |
| 2016 FY | 93.43 Million EUR | 81.9% |
| 2015 FY | 51.36 Million EUR | 17.98% |
| 2015 Q4 | 14.35 Million EUR | 17.64% |
| 2015 Q3 | 12.2 Million EUR | -15.79% |
| 2015 Q2 | 14.49 Million EUR | 40.46% |
| 2015 Q1 | 10.31 Million EUR | -27.8% |
| 2014 Q2 | 11.02 Million EUR | 6.35% |
| 2014 Q1 | 10.37 Million EUR | 41.11% |
| 2014 Q3 | 7.84 Million EUR | -28.87% |
| 2014 FY | 43.53 Million EUR | 20.75% |
| 2014 Q4 | 14.28 Million EUR | 82.14% |
| 2013 Q3 | 16.8 Million EUR | 98.42% |
| 2013 Q4 | 7.34 Million EUR | -56.28% |
| 2013 FY | 36.05 Million EUR | 121.67% |
| 2013 Q2 | 8.47 Million EUR | 167.98% |
| 2013 Q1 | 3.16 Million EUR | -29.28% |
| 2012 FY | 16.26 Million EUR | 88.09% |
| 2012 Q3 | 3.44 Million EUR | 0.0% |
| 2012 Q4 | 4.47 Million EUR | 29.83% |
| 2011 FY | 8.64 Million EUR | -48.57% |
| 2010 FY | 16.81 Million EUR | 397.1% |
| 2009 FY | 3.38 Million EUR | -11.63% |
| 2008 FY | 3.82 Million EUR | -3.55% |
| 2007 FY | 3.96 Million EUR | 117.54% |
| 2006 FY | 1.82 Million EUR | -54.01% |
| 2005 FY | 3.96 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -1211.852% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -4803.501% |
| XOMA Corporation | 46.46 Million USD | -190.39% |
| Mesoblast Limited | 5.9 Million USD | -2186.073% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | 19.896% |
| Aptorum Group Limited | 10.56 Thousand USD | -1276863.846% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -2113.463% |
| HilleVax, Inc. | 133.34 Million USD | -1.184% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | 48.038% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -870.003% |
| Precision BioSciences, Inc. | 92.46 Million USD | -45.922% |
| Dyadic International, Inc. | 9.15 Million USD | -1374.145% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -1521.878% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | 14.504% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -506.318% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -354.565% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -15.861% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 58.067% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -2.844% |
| IGM Biosciences, Inc. | 265.59 Million USD | 49.199% |
| Opthea Limited | 191.96 Million USD | 29.715% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -117.276% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -652.127% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -11.134% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -60.009% |
| NextCure, Inc. | 67.63 Million USD | -99.483% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -1904.235% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -126.105% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -187.036% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | 44.93% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -338.478% |
| Senti Biosciences, Inc. | 94.7 Million USD | -42.468% |
| Apollomics, Inc. | 54.14 Million USD | -149.213% |
| PureTech Health plc | 144.59 Million USD | 6.69% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -958.56% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -59.266% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | 44.731% |
| ChromaDex Corporation | 56.37 Million USD | -139.316% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -1427.804% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | 32.912% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 40.999% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -1577.761% |
| Gritstone bio, Inc. | 148.37 Million USD | 9.065% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -759.948% |
| Fate Therapeutics, Inc. | 254.04 Million USD | 46.89% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | 21.511% |
| Fortress Biotech, Inc. | 200.19 Million USD | 32.604% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -158.223% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -330.009% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | 45.405% |
| Celcuity Inc. | 66.23 Million USD | -103.719% |
| ContextLogic Inc. | 387 Million USD | 65.136% |
| GH Research PLC | 41.22 Million USD | -227.311% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -312.032% |
| Cassava Sciences, Inc. | 105.95 Million USD | -27.338% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -421.486% |
| ImmuCell Corporation | 9.61 Million USD | -1302.921% |
| Amarin Corporation plc | 272.35 Million USD | 50.461% |
| TG Therapeutics, Inc. | 198.47 Million USD | 32.02% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -25.485% |
| Acelyrin, Inc. | 422.06 Million USD | 68.032% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -304.812% |
| Seer, Inc. | 110.49 Million USD | -22.114% |
| Novavax, Inc. | 779.12 Million USD | 82.683% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | 19.605% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 95.856% |
| AnaptysBio, Inc. | 181.56 Million USD | 25.69% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -367.221% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -68.377% |
| AbCellera Biologics Inc. | 275.23 Million USD | 50.978% |
| CorMedix Inc. | 48.95 Million USD | -175.593% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -21.699% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -654.081% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 95.207% |
| Aptose Biosciences Inc. | 52.35 Million USD | -157.705% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -836.298% |
| Soligenix, Inc. | 7.79 Million USD | -1630.849% |
| Century Therapeutics, Inc. | 56.07 Million USD | -140.631% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 69.73% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -594.821% |
| Kura Oncology, Inc. | 165.8 Million USD | 18.624% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -6.188% |
| Ardelyx, Inc. | 169.93 Million USD | 20.604% |
| Ainos, Inc. | 12.95 Million USD | -941.67% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -17.83% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -5336.891% |
| Prothena Corporation plc | 282.4 Million USD | 52.223% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -25.28% |
| Autolus Therapeutics plc | 196.72 Million USD | 31.415% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -59.377% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | 32.545% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -596.095% |
| Celularity Inc. | 215.05 Million USD | 37.262% |
| Rallybio Corporation | 78.93 Million USD | -70.937% |
| GRI Bio, Inc. | 11.33 Million USD | -1090.856% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -1812.269% |
| Omeros Corporation | 94.75 Million USD | -42.398% |
| INmune Bio, Inc. | 29.89 Million USD | -351.311% |
| Heron Therapeutics, Inc. | 172.55 Million USD | 21.808% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -234.68% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -744.364% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -757.12% |
| Humacyte, Inc. | 23.49 Million USD | -474.218% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 51.06% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 55.242% |
| Immunocore Holdings plc | 308.04 Million USD | 56.199% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -3880.059% |
| Verastem, Inc. | 92.08 Million USD | -46.523% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | 27.353% |
| Histogen Inc. | 14.27 Million USD | -845.376% |
| Surrozen, Inc. | 18.55 Million USD | -627.353% |
| Blueprint Medicines Corporation | 722.86 Million USD | 81.335% |
| Organovo Holdings, Inc. | 14.91 Million USD | -804.62% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -2550.643% |
| IO Biotech, Inc. | 91.44 Million USD | -47.55% |
| MEI Pharma, Inc. | 34.78 Million USD | -287.88% |
| GT Biopharma, Inc. | 13.57 Million USD | -893.842% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | 24.258% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -178.493% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -80.718% |
| Summit Therapeutics Inc. | 87.68 Million USD | -53.872% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -357.851% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | 15.956% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -778.036% |
| Turnstone Biologics Corp. | 78.33 Million USD | -72.233% |
| Pulmatrix, Inc. | 22.03 Million USD | -512.233% |
| Synaptogenix, Inc. | 8.31 Million USD | -1522.882% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -825.024% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | 46.682% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -51.829% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 75.538% |
| Cytokinetics, Incorporated | 173.61 Million USD | 22.284% |
| Exelixis, Inc. | 1.58 Billion USD | 91.497% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | 41.856% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 84.223% |
| Evogene Ltd. | 27.79 Million USD | -385.513% |
| Replimune Group, Inc. | 234.77 Million USD | 42.53% |
| PDS Biotechnology Corporation | 43.04 Million USD | -213.447% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -1654.027% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -95.937% |
| ESSA Pharma Inc. | 32.13 Million USD | -319.878% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -724.708% |
| BioLineRx Ltd. | 50.8 Million USD | -165.588% |
| Avid Bioservices, Inc. | 25.99 Million USD | -419.018% |
| Insmed Incorporated | 949.26 Million USD | 85.786% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -295.846% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | 46.576% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -312.108% |
| MediWound Ltd. | 18.86 Million USD | -615.094% |
| MiMedx Group, Inc. | 229.72 Million USD | 41.268% |
| OmniAb, Inc. | 83.89 Million USD | -60.825% |
| Alector, Inc. | 248.8 Million USD | 45.771% |
| Seres Therapeutics, Inc. | 234.3 Million USD | 42.416% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 89.715% |
| Mereo BioPharma Group plc | 35.84 Million USD | -276.441% |
| Zai Lab Limited | 547.47 Million USD | 75.355% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 66.155% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | 41.326% |
| Aura Biosciences, Inc. | 84.99 Million USD | -58.751% |
| Immunic, Inc. | 99.22 Million USD | -35.981% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | 44.284% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | 15.149% |
| Veracyte, Inc. | 357.93 Million USD | 62.305% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 98.503% |
| FibroGen, Inc. | 398.11 Million USD | 66.109% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -849.5% |
| Allakos Inc. | 196.05 Million USD | 31.181% |
| scPharmaceuticals Inc. | 65.17 Million USD | -107.008% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -18.908% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 63.397% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -1858.842% |
| NLS Pharmaceutics AG | 11.8 Million USD | -1042.74% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -1793.476% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 57.376% |
| Precigen, Inc. | 84.18 Million USD | -60.278% |
| Fortrea Holdings Inc. | 457.3 Million USD | 70.496% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -148.58% |
| Incyte Corporation | 1.19 Billion USD | 88.667% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -1257.706% |
| Cara Therapeutics, Inc. | 142.46 Million USD | 5.292% |
| XBiotech Inc. | 37.51 Million USD | -259.701% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -30.165% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -95.937% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -455.092% |
| CRISPR Therapeutics AG | 463.49 Million USD | 70.89% |
| Akero Therapeutics, Inc. | 172.87 Million USD | 21.951% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -260.682% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -553.417% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | 5.024% |
| Agenus Inc. | 78.18 Million USD | -72.575% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -971.94% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -36.184% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -21.865% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 85.92% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -367.755% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -1905.193% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 68.669% |
| UroGen Pharma Ltd. | 138.88 Million USD | 2.854% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -504.815% |
| Sutro Biopharma, Inc. | 243 Million USD | 44.478% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -2339.437% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -424.833% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -429.966% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -9.203% |
| Chimerix, Inc. | 93.38 Million USD | -44.475% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -62.455% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -153.968% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -2634.795% |
| Pluri Inc. | 22.48 Million USD | -500.196% |
| Cue Biopharma, Inc. | 19.54 Million USD | -590.431% |
| MeiraGTx Holdings plc | 151.07 Million USD | 10.692% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -740.745% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -1667.677% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -55.326% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -1496.217% |
| CalciMedica, Inc. | 21.81 Million USD | -518.435% |
| Scholar Rock Holding Corporation | 171.29 Million USD | 21.233% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 54.254% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -290.236% |
| NLS Pharmaceutics AG | 11.8 Million USD | -1042.74% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -85.971% |
| Nutriband Inc. | 5.73 Million USD | -2253.039% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -209.366% |
| Vor Biopharma Inc. | 126.03 Million USD | -7.052% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 88.654% |
| ProKidney Corp. | 151.52 Million USD | 10.954% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -81.9% |
| Daré Bioscience, Inc. | 33.6 Million USD | -301.447% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 78.034% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -1708.39% |
| Bicycle Therapeutics plc | 216.92 Million USD | 37.801% |
| Tango Therapeutics, Inc. | 150.7 Million USD | 10.468% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -254.392% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 72.948% |
| Atai Life Sciences N.V. | 125.78 Million USD | -7.266% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -65.268% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -65.736% |
| MediciNova, Inc. | 10.9 Million USD | -1137.805% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -4.738% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -1758.579% |
| GeoVax Labs, Inc. | 6.02 Million USD | -2140.454% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | 12.189% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 71.676% |
| Biomea Fusion, Inc. | 126.13 Million USD | -6.968% |
| RenovoRx, Inc. | 11.39 Million USD | -1083.959% |
| Erasca, Inc. | 141.52 Million USD | 4.664% |
| Cullinan Oncology, Inc. | 191.08 Million USD | 29.392% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -389.174% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -0.999% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | 48.512% |
| bluebird bio, Inc. | 240.23 Million USD | 43.836% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | 35.131% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -85.933% |
| Imunon, Inc. | 20.31 Million USD | -564.309% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 92.274% |
| BioAtla, Inc. | 129.68 Million USD | -4.038% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -58.887% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -223.109% |
| DBV Technologies S.A. | 92.16 Million USD | -46.402% |
| Fortress Biotech, Inc. | 200.19 Million USD | 32.604% |
| Avidity Biosciences, Inc. | 245.15 Million USD | 44.964% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -21.366% |
| aTyr Pharma, Inc. | 12.97 Million USD | -939.556% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 47.04% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -1540.45% |
| Galecto, Inc. | 35.62 Million USD | -278.713% |
| Akari Therapeutics, Plc | 16.8 Million USD | -702.832% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -5833.412% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 54.923% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | 21.95% |
| Entera Bio Ltd. | 8.86 Million USD | -1422.844% |
| Travere Therapeutics, Inc. | 472 Million USD | 71.415% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -264.03% |
| Xencor, Inc. | 306.97 Million USD | 56.048% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -149.49% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -117.332% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -558.491% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | 29.652% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -1905.193% |
| Portage Biotech Inc. | 18.19 Million USD | -641.381% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -1758.579% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -28.547% |
| OncoCyte Corporation | 25.63 Million USD | -426.286% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -1077.649% |
| Purple Biotech Ltd. | -22.46 Million USD | 700.543% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -718.714% |
| Onconetix, Inc. | 34.9 Million USD | -286.519% |
| MacroGenics, Inc. | 217.21 Million USD | 37.885% |
| Tharimmune, Inc. | 9.45 Million USD | -1326.979% |
| Genprex, Inc. | 31.06 Million USD | -334.39% |
| Apogee Therapeutics, Inc. | 93 Million USD | -45.075% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | 28.051% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -355.732% |
| Prime Medicine, Inc. | 186.63 Million USD | 27.709% |
| Aditxt, Inc. | 25.95 Million USD | -419.923% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -17537.124% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -2377.07% |
| OKYO Pharma Limited | 8243.57 USD | -1636618.072% |
| Savara Inc. | 15.74 Million USD | -756.932% |
| Curis, Inc. | 58.35 Million USD | -131.212% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -2549.471% |
| Adagene Inc. | 41.83 Million USD | -222.543% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -399.312% |
| BeiGene, Ltd. | 3.28 Billion USD | 95.895% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | 38.623% |
| GlycoMimetics, Inc. | 39.28 Million USD | -243.447% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | 21.487% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -2880.446% |
| SciSparc Ltd. | 9.01 Million USD | -1397.325% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -2880.446% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -216.656% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -1458.614% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -484.375% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -839.19% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 54.374% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -102.282% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 92.504% |
| ADMA Biologics, Inc. | 66.58 Million USD | -102.631% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -3.578% |
| Clene Inc. | 41.07 Million USD | -228.498% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -210.785% |
| Cogent Biosciences, Inc. | 208.13 Million USD | 35.173% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -146.23% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 61.675% |
| Adicet Bio, Inc. | 152.03 Million USD | 11.256% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -300.036% |
| Absci Corporation | 73.66 Million USD | -83.156% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -1745.721% |
| Quantum-Si incorporated | 111.65 Million USD | -20.836% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -825.546% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -276.651% |
| Surrozen, Inc. | 18.55 Million USD | -627.353% |
| Generation Bio Co. | 144.46 Million USD | 6.606% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -62.5% |
| Caribou Biosciences, Inc. | 150.53 Million USD | 10.371% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -56.054% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -66.445% |
| Invivyd, Inc. | 205.75 Million USD | 34.425% |
| Cingulate Inc. | 22.75 Million USD | -492.833% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -86.982% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -1338.652% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -1538.632% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -79.291% |
| Jaguar Health, Inc. | 42.01 Million USD | -221.133% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -1211.597% |
| 2seventy bio, Inc. | 289.88 Million USD | 53.456% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -312.422% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -31.559% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 82.108% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -953.445% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -267.32% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -30.107% |
| Kronos Bio, Inc. | 128.11 Million USD | -5.312% |
| Innoviva, Inc. | 132.15 Million USD | -2.096% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -60.486% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -2.08% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | 20.763% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 82.425% |
| Evaxion Biotech A/S | 22.27 Million USD | -505.855% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | 0.457% |
| Verve Therapeutics, Inc. | 234.88 Million USD | 42.557% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -68.771% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 1900.908% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -202.066% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -117.36% |
| Clearmind Medicine Inc. | 8.74 Million USD | -1443.514% |
| AlloVir, Inc. | 180.93 Million USD | 25.429% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -21.795% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | 47.991% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -4500.228% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -33.817% |
| Keros Therapeutics, Inc. | 169.27 Million USD | 20.294% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -256.291% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | 40.463% |
| ImmunityBio, Inc. | 362.87 Million USD | 62.818% |
| Korro Bio, Inc. | 84.53 Million USD | -59.609% |
| C4 Therapeutics, Inc. | 159.78 Million USD | 15.56% |
| Kineta, Inc. | 21.15 Million USD | -537.758% |
| Lantern Pharma Inc. | 17.87 Million USD | -654.711% |
| BioVie Inc. | 31.95 Million USD | -322.295% |
| Codexis, Inc. | 66.51 Million USD | -102.838% |
| Celularity Inc. | 215.05 Million USD | 37.262% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -213.777% |
| Virax Biolabs Group Limited | 6.54 Million USD | -1960.832% |
| Kodiak Sciences Inc. | 277.32 Million USD | 51.347% |
| Cibus, Inc. | 320.3 Million USD | 57.876% |
| Annexon, Inc. | 143.72 Million USD | 6.122% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -488.956% |
| Moderna, Inc. | 6.39 Billion USD | 97.89% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 82.693% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -5.747% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -20981.875% |
| Immix Biopharma, Inc. | 16.14 Million USD | -735.903% |
| Eyenovia, Inc. | 25.4 Million USD | -431.062% |
| Puma Biotechnology, Inc. | 140.31 Million USD | 3.842% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | 5.852% |
| Wave Life Sciences Ltd. | 181.3 Million USD | 25.58% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -2325.818% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -70.503% |
| Alkermes plc | 996.24 Million USD | 86.457% |
| Arcellx, Inc. | 200.19 Million USD | 32.605% |
| Moolec Science SA | 52.75 Million USD | -155.777% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -193.952% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -189.91% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | 37.654% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -1255.067% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -43.426% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -178.349% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -1346.462% |
| Humacyte, Inc. | 23.49 Million USD | -474.218% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -120.688% |
| Geron Corporation | 70.44 Million USD | -91.542% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -91.127% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -827.95% |
| Royalty Pharma plc | 862.4 Million USD | 84.355% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -496.256% |
| Notable Labs, Ltd. | 14.77 Million USD | -813.5% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | 35.074% |
| Structure Therapeutics Inc. | 102.77 Million USD | -31.281% |
| IN8bio, Inc. | 30.33 Million USD | -344.751% |
| 89bio, Inc. | 151.2 Million USD | 10.767% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -534.429% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -32.263% |
| Acasti Pharma Inc. | 11.3 Million USD | -1093.912% |
| Genelux Corporation | 24.33 Million USD | -454.444% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -297.736% |
| Liquidia Corporation | 87.98 Million USD | -53.351% |
| Mustang Bio, Inc. | 48.5 Million USD | -178.188% |
| Immunovant, Inc. | 282.7 Million USD | 52.275% |
| Vericel Corporation | 142.04 Million USD | 5.01% |
| Quantum-Si incorporated | 111.65 Million USD | -20.836% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -498.492% |
| XOMA Corporation | 46.46 Million USD | -190.39% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -99.739% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -488.645% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -744.364% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 478.15% |
| Vaxcyte, Inc. | 468.04 Million USD | 71.173% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -189.897% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -1745.721% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -749.326% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -362.75% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -337.227% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | 46.561% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -226.029% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -359.003% |
| PepGen Inc. | 84.76 Million USD | -59.172% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -355.347% |
| United Therapeutics Corporation | 885.1 Million USD | 84.756% |
| Solid Biosciences Inc. | 104.31 Million USD | -29.343% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -312.29% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -2325.818% |
| Immuneering Corporation | 58.41 Million USD | -130.983% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -2550.643% |
| Silo Pharma, Inc. | 3.92 Million USD | -3340.31% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -3322.688% |
| Belite Bio, Inc | 31.66 Million USD | -326.058% |
| Pharming Group N.V. | 225.49 Million USD | 40.164% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -455.092% |
| Bionomics Limited | 17.89 Billion USD | 99.246% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -64.149% |
| uniQure N.V. | 285.08 Million USD | 52.673% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -672.893% |
| GeoVax Labs, Inc. | 6.02 Million USD | -2140.454% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | 30.526% |
| Altimmune, Inc. | 30.55 Million USD | -341.563% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -1523.877% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 478.15% |
| Peak Bio, Inc. | 1249.13 USD | -10801337.801% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -849.5% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -1417.876% |
| Benitec Biopharma Inc. | 22.38 Million USD | -502.824% |
| Zura Bio Limited | 62.63 Million USD | -115.403% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 68.45% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -1046309.183% |
| Compugen Ltd. | 43.97 Million USD | -206.848% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -11791.978% |
| argenx SE | 1.53 Billion USD | 91.202% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -82.035% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -489.265% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | 44.519% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -372.704% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 64.54% |
| PolyPid Ltd. | 21.04 Million USD | -541.121% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -728.975% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -1479.167% |
| Forte Biosciences, Inc. | 32.47 Million USD | -315.445% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -164.557% |
| Instil Bio, Inc. | 85.78 Million USD | -57.282% |
| Elevation Oncology, Inc. | 45.44 Million USD | -196.895% |
| Immunome, Inc. | 122.82 Million USD | -9.855% |
| Verona Pharma plc | 67.15 Million USD | -100.925% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -720.284% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -421.244% |
| Shattuck Labs, Inc. | 93.61 Million USD | -44.128% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -90.832% |
| Design Therapeutics, Inc. | 78.19 Million USD | -72.559% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -55.012% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -972.102% |
| Achilles Therapeutics plc | 75.25 Million USD | -79.289% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -165.186% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -104.124% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -149.291% |
| Beam Therapeutics Inc. | 554.19 Million USD | 75.654% |
| Moolec Science SA | 52.75 Million USD | -155.777% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -137.714% |
| AEON Biopharma, Inc. | 48.42 Million USD | -178.602% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -44.338% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -61.53% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 70.083% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -53.515% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -1.787% |
| Athira Pharma, Inc. | 125.46 Million USD | -7.538% |
| HCW Biologics Inc. | 21.02 Million USD | -541.654% |
| XOMA Corporation | 46.46 Million USD | -190.39% |
| NeurAxis, Inc. | 8.82 Million USD | -1429.543% |
| Lumos Pharma, Inc. | 38.66 Million USD | -248.956% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -421.244% |
| 180 Life Sciences Corp. | 13.47 Million USD | -901.106% |
| Nektar Therapeutics | 190.9 Million USD | 29.323% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -372.704% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -409.1% |
| Arvinas, Inc. | 480 Million USD | 71.891% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -4500.228% |
| Palisade Bio, Inc. | 13.32 Million USD | -912.943% |
| Nutriband Inc. | 5.73 Million USD | -2253.039% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -5833.412% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -142.438% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -197.131% |
| Merus N.V. | 200.49 Million USD | 32.704% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -30.544% |
| Neurogene Inc. | 55.58 Million USD | -142.743% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | 45.702% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -1496.545% |
| CervoMed Inc. | 14.95 Million USD | -802.033% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -39.514% |
| Sesen Bio, Inc. | 78.38 Million USD | -72.139% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -289.728% |
| Rezolute, Inc. | 70.38 Million USD | -91.689% |
| Clene Inc. | 41.07 Million USD | -228.498% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -723.789% |
| BeyondSpring Inc. | 24.86 Million USD | -442.626% |
| Synlogic, Inc. | 58.53 Million USD | -130.513% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -654.102% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -2903.651% |
| Peak Bio, Inc. | 1249.13 USD | -10801337.801% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -123.214% |
| Krystal Biotech, Inc. | 160.42 Million USD | 15.896% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | 50.145% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 61.233% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -6155.941% |
| MannKind Corporation | 125.59 Million USD | -7.426% |
| Ikena Oncology, Inc. | 84.57 Million USD | -59.528% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -1298.611% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -50.583% |
| Gossamer Bio, Inc. | 183.75 Million USD | 26.576% |
| CohBar, Inc. | 12.38 Million USD | -989.125% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -165.996% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -389.174% |
| Legend Biotech Corporation | 583.14 Million USD | 76.863% |
| Mural Oncology plc | 192.07 Million USD | 29.753% |
| Disc Medicine, Inc. | 91.12 Million USD | -48.065% |
| Champions Oncology, Inc. | 28.11 Million USD | -379.986% |
| REGENXBIO Inc. | 321.15 Million USD | 57.988% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -2416.659% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -141.99% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -246.308% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -17.985% |
| Vaxart, Inc. | 90.72 Million USD | -48.716% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -1483.614% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -215.287% |
| Cellectis S.A. | 97.32 Million USD | -38.64% |
| Longeveron Inc. | 21.25 Million USD | -534.936% |
| Repare Therapeutics Inc. | 167.35 Million USD | 19.38% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 90.085% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -78.365% |
| Revolution Medicines, Inc. | 498.76 Million USD | 72.948% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -1928.322% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -206.966% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -80.888% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -93.759% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -1119.928% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 97.174% |
| Denali Therapeutics Inc. | 527.23 Million USD | 74.409% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -1458.614% |
| Veru Inc. | 101.34 Million USD | -33.129% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -476.426% |
| Cingulate Inc. | 22.75 Million USD | -492.833% |
| Passage Bio, Inc. | 108.38 Million USD | -24.481% |
| Context Therapeutics Inc. | 25.07 Million USD | -438.133% |
| Exicure, Inc. | 14.07 Million USD | -858.539% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | 34.523% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -211.596% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -1370.194% |
| Nuvalent, Inc. | 149.49 Million USD | 9.745% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -1572.563% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -30.173% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -529.046% |
| OmniAb, Inc. | 83.89 Million USD | -60.825% |
| Anew Medical, Inc. | 1.3 Million USD | -10272.059% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -311.806% |
| Lipocine Inc. | 15.08 Million USD | -794.713% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -96.932% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -77.177% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -234.68% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -17.486% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -502.77% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 79.685% |
| Ocugen, Inc. | 71.56 Million USD | -88.528% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -43.741% |
| Q32 Bio Inc. | 92.68 Million USD | -45.58% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -537.215% |
| Alumis Inc. Common Stock | 158.17 Million USD | 14.699% |
| Equillium, Inc. | 50.6 Million USD | -166.617% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -116.204% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -870.288% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -615.204% |
| Dominari Holdings Inc. | 23.83 Million USD | -466.075% |
| Edesa Biotech, Inc. | 9.22 Million USD | -1362.946% |
| vTv Therapeutics Inc. | 11.9 Million USD | -1033.149% |
| Bio-Techne Corporation | 563.03 Million USD | 76.036% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 66.996% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | 49.797% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -2.001% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -836.257% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | 17.576% |
| Nkarta, Inc. | 131.65 Million USD | -2.487% |
| BioCardia, Inc. | 12.12 Million USD | -1013.142% |
| Iterum Therapeutics plc | 47.46 Million USD | -184.242% |